(Q46744451)

24 December 2017

title

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen (English)

1 reference

24 December 2017

1 reference

Hagen Kennecke

1

1 reference

24 December 2017

Heather McArthur

2

1 reference

24 December 2017

Ivo A Olivotto

3

1 reference

24 December 2017

Caroline Speers

4

1 reference

24 December 2017

Chris Bajdik

5

1 reference

24 December 2017

Stephen K Chia

6

1 reference

24 December 2017

Susan Ellard

7

1 reference

24 December 2017

Brian Norris

8

1 reference

24 December 2017

Malcolm Hayes

9

1 reference

24 December 2017

Jeff Barnett

10

1 reference

24 December 2017

Karen A Gelmon

11

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

1437-1444

1 reference

24 December 2017

The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Compliance with practice guidelines for node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23320

7 January 2021

Identifiers

DOI

10.1002/CNCR.23320

1 reference

24 December 2017

release_tdfuqvys3rap3biefk3xgw4q5q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tdfuqvys3rap3biefk3xgw4q5q

24 November 2022

mapped directly with Wikidata item

1 reference

24 December 2017